{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:18:48Z","timestamp":1789154328774,"version":"build-2803163510"},"reference-count":155,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>An apparent paradox exists between the evidence for spontaneous systemic T cell- mediated anti-tumor immune responses in cancer patients, observed particularly in their bone marrow, and local tumor growth in the periphery. This phenomenon, known as \u201cconcomitant immunity\u201d suggests that the local tumor and its tumor microenvironment (TME) prevent systemic antitumor immunity to become effective. Oncolytic Newcastle disease virus (NDV), an agent with inherent anti-neoplastic and immune stimulatory properties, is capable of breaking therapy resistance and immunosuppression. This review updates latest information about immunosuppression by the TME and discusses mechanisms of how oncolytic viruses, in particular NDV, and cellular immunotherapy can counteract the immunosuppressive effect of the TME. With regard to cellular immunotherapy, the review presents pre-clinical studies of post-operative active-specific immunotherapy and of adoptive T cell-mediated therapy in immunocompetent mice. Memory T cell (MTC) transfer in tumor challenged T cell-deficient nu\/nu mice demonstrates longevity and functionality of these cells. Graft-versus-leukemia (GvL) studies in mice demonstrate complete remission of late-stage disease including metastases and cachexia. T cell based immunotherapy studies with human cells in human tumor xenotransplanted NOD\/SCID mice demonstrate superiority of bone marrow-derived as compared to blood-derived MTCs. Results from clinical studies presented include vaccination studies using two different types of NDV-modified cancer vaccine and a pilot adoptive T-cell mediated therapy study using re-activated bone marrow-derived cancer-reactive MTCs. As an example for what can be expected from clinical immunotherapy against tumors with an immunosuppressive TME, results from vaccination studies are presented from the aggressive brain tumor glioblastoma multiforme. The last decades of basic research in virology, oncology and immunology can be considered as a success story. Based on discoveries of these research areas, translational research and clinical studies have changed the way of treatment of cancer by introducing and including immunotherapy.<\/jats:p>","DOI":"10.3390\/ijms232113050","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T20:37:58Z","timestamp":1666903078000},"page":"13050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-9145","authenticated-orcid":false,"given":"Volker","family":"Schirrmacher","sequence":"first","affiliation":[{"name":"Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"van Gool","sequence":"additional","affiliation":[{"name":"Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Stuecker","sequence":"additional","affiliation":[{"name":"Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Burman, B., Pesci, G., and Zamarin, D. (2020). Newcastle disease virus at the forefront of cancer immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12123552"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2101672","DOI":"10.1002\/advs.202101672","article-title":"Targeted anti-tumor immunotherapy using tumor infiltrating cells","volume":"8","author":"Xie","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1073\/pnas.91.16.7430","article-title":"Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection","volume":"91","author":"Khazaie","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm914","article-title":"Bone marrow as a priming site for T-cell responses to blood-borne antigen","volume":"9","author":"Feuerer","year":"2003","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0008-8749(03)00062-5","article-title":"A novel tumour model system for the study of long-term protective immunity and immune T cell memory","volume":"221","author":"Mahnke","year":"2003","journal-title":"Cell. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2567.2005.02163.x","article-title":"Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells","volume":"115","author":"Mahnke","year":"2005","journal-title":"Immunology"},{"key":"ref_7","first-page":"51","article-title":"Bone marrow T cells and the integrated functions of recirculating and tissue-resident memory T cells","volume":"7","author":"Gebhardt","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1172\/JCI97454","article-title":"Redirection to the bone marrow improves T cell persistence and antitumor functions","volume":"128","author":"Khan","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Macallan, D.C., Borghans, J.A.M., and Asquith, B. (2017). Human T cell memory: A dynamic view. Vaccines, 5.","DOI":"10.3390\/vaccines5010005"},{"key":"ref_10","first-page":"867","article-title":"Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory","volume":"25","author":"Feuerer","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.molmed.2003.10.001","article-title":"T-cell priming in bone marrow: The potential for long-lasting protective anti-tumor immunity","volume":"8","author":"Schirrmacher","year":"2003","journal-title":"Trends Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1349-7006.2009.01468.x","article-title":"High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: An important role of bone marrow as a secondary lymphoid organ","volume":"101","author":"Murao","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2020). New insights into mechanisms of long-term protective anti-tumor immunity induced by cancer vaccines modified by virus infection. Biomedicines, 8.","DOI":"10.3390\/biomedicines8030055"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"a038083","DOI":"10.1101\/cshperspect.a038083","article-title":"Homeostasis and durability of T-cell memory- The resting and the restless T-cell memory","volume":"13","author":"Radbruch","year":"2021","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","article-title":"Anti-tumor immunity controlled through mRNA m6A and YTHDF1 in dendritic cells","volume":"566","author":"Han","year":"2019","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumor immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yefenof, E., and Witz, I. (2008). Local tumor growth and spontaneous systemic T cell responses in cancer patients: A paradox and puzzle. Innate and Adaptive Immunity in the Tumor Microenvironment, Springer Science + Business Media.","DOI":"10.1007\/978-1-4020-6750-1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1158\/0008-5472.CAN-05-4201","article-title":"The shaping of a polyvalent and highly individual T cell repertoire in the bone marrow of breast cancer patients","volume":"66","author":"Sommerfeldt","year":"2006","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q","article-title":"Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients","volume":"92","author":"Feuerer","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1158\/0008-5472.CAN-05-1098","article-title":"High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients","volume":"65","author":"Volk","year":"2005","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.10781","article-title":"Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: Bidirectional cell stimulation, survival and antitumor activity in vivo","volume":"103","author":"Bai","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/86523","article-title":"Therapy of human tumors in NOD\/SCID mice with patient-derived reactivated memory T cells from bone marrow","volume":"7","author":"Feuerer","year":"2001","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI200420278","article-title":"Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors","volume":"114","author":"Beckhove","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3892\/ijo.2015.3197","article-title":"Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential (Review)","volume":"47","author":"Schirrmacher","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00262-008-0605-3","article-title":"Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: A pilot clinical study","volume":"58","author":"Schuetz","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00262-013-1414-x","article-title":"Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: Follow-up analysis of a clinical pilot trial","volume":"62","author":"Domschke","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","first-page":"505","article-title":"Effective immune rejection of advanced metastasized cancer","volume":"6","author":"Schirrmacher","year":"1995","journal-title":"Int. J. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00262-014-1530-2","article-title":"Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: Lessons from GvL studies in animals","volume":"63","author":"Schirrmacher","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fcell.2015.00033","article-title":"A top-down view of the tumor microenvironment: Structure, cells and signaling","volume":"3","author":"Bhome","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sethakorn, N., Henninger, E., Sanchez-de-Diego, C., Ding, A.B., Yada, R.C., Kerr, S.C., Kosoff, D., Beebe, D.J., and Lang, J.M. (2022). Advancing treatment of bone metastases through novel translational approaches targeting the bone microenvironment. Cancers, 14.","DOI":"10.3390\/cancers14030757"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10555-012-9397-1","article-title":"Bone marrow microenvironment in cancer patients: Immunological aspects and clinical implications","volume":"32","author":"Stefanovic","year":"2013","journal-title":"Cancer Met. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tcb.2021.11.008","article-title":"Differentiation of the tumor microenvironment: Are CAFs the organizers ?","volume":"32","author":"Kochetkova","year":"2022","journal-title":"Trends Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ghahremanifard, P., Chanda, A., Bonni, S., and Bose, P. (2020). TGF-\u00df mediated immune evasion in cancer\u2013spotlight on cancer-associated fibroblasts. Cancers, 12.","DOI":"10.3390\/cancers12123650"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sperb, N., Tsesmelis, M., and Wirth, T. (2020). Crosstalk between tumor and stromal cells in pancreatic ductal adenocarcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155486"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Czekay, R., Cheon, D., Samarakoon, R., Kutz, S.M., and Higgins, P.J. (2022). Cancer-associated fibroblasts: Mechanisms of tumor progression and novel therapeutic targets. Cancers, 14.","DOI":"10.3390\/cancers14051231"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","article-title":"TGF-\u00df modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment","volume":"73","author":"Yeung","year":"2013","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: From molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"894306","DOI":"10.3389\/fimmu.2022.894306","article-title":"Greek fire, poison arrows, and scorpion bombs: How tumor cells defend against the siege weapons of cytotoxic T lymphocytes","volume":"13","author":"McKenzie","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_43","first-page":"485","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gumberger, P., Bjornsson, B., Sandstr\u00f6m, P., Bojmar, L., and Zambirinis, C. (2022). The liver pre-metastatic niche in pancreatic cancer: A potential opportunity for intervention. Cancers, 14.","DOI":"10.3390\/cancers14123028"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1158\/0008-5472.CAN-20-4125","article-title":"TIMP1 triggers neutrophil extracellular trap formation in pancreatic cancer","volume":"81","author":"Schoeps","year":"2021","journal-title":"Caner Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","article-title":"Targeting tumor-associated macrophages for cancer treatment","volume":"12","author":"Li","year":"2022","journal-title":"Cell Biosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.ymthe.2022.01.046","article-title":"Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment","volume":"30","author":"Xu","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/bph.15373","article-title":"STAT3\/NF-kB signalling disruption in M2 tumor-associated macrophages is a major target of PLGA nanocarriers\/PD-L1 antibody immunomodulatory therapy in breast cancer","volume":"178","author":"Cavalcante","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","article-title":"Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer","volume":"37","author":"Hedge","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","article-title":"Suppression of antitumor immunity by IL-10 and TGF\u00df producing T cell infiltrating the growing tumour: Influence of tumour microenvironment on the induction of CD4+ and CD8+ regulatory T cells","volume":"177","author":"Jarnicki","year":"2006","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Nam, J.-H., Lee, J.-H., Choi, S.-Y., Jung, N.-C., Song, J.-Y., Seo, H.-G., and Lim, D.-S. (2021). Functional ambivalence of dendritic cells: Tolerogenicity and immunogenicity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094430"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eabm0631","DOI":"10.1126\/sciimmunol.abm0631","article-title":"Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Baldanzi, G. (2022). Immune checkpoint receptors signaling in T cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073529"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"845064","DOI":"10.3389\/fimmu.2022.845064","article-title":"RhoG\u2019s role in T cell activation and function","volume":"13","author":"Mokhtar","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e004605","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1238","DOI":"10.1002\/cti2.1238","article-title":"Arrested development: Suppression of NK cell function in the tumor microenvironment","volume":"10","author":"Riggan","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"803014","DOI":"10.3389\/fimmu.2021.803014","article-title":"Polymorphonuclear myeloid-derived suppressor cells are abundant in peripheral blood of cancer patients and suppress Natural killer cell anti-tumor activity","volume":"12","author":"Tumino","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-21-1052","article-title":"TGF-\u00df and CIS overcomes NK cell suppression to restore anti-tumor immunity","volume":"10","author":"Guimaraes","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10555-006-9010-6","article-title":"Intratumoral cytokines, chemokines\/growth factors and tumour infiltrating dendritic cells: Friends or enemies?","volume":"25","author":"Shurin","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e55185","DOI":"10.7554\/eLife.55185","article-title":"The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy","volume":"9","author":"Lim","year":"2020","journal-title":"eLife"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tirpe, A.A., Gulei, D., Ciortea, S.M., Crivii, C., and Berindan-Neagoe, I. (2019). Hypoxia: Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246140"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"913184","DOI":"10.3389\/fimmu.2022.913184","article-title":"TGF\u00df limits Myc-dependent TCR-induced metabolic reprogramming in CD8+ T cells","volume":"13","author":"Hope","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Rentschler, M., Braum\u00fcller, H., Briquez, P.S., and Wieder, T. (2022). Cytokine-induced senescence in the tumor microenvironment and its effects on anti-tumor immune responses. Cancers, 14.","DOI":"10.3390\/cancers14061364"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0171-2985(80)80091-X","article-title":"Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis","volume":"157","author":"Schirrmacher","year":"1980","journal-title":"Immunobiology"},{"key":"ref_69","first-page":"4105","article-title":"Specificity of arrest, survival, and growth of selected metastatic variant cell lines","volume":"38","author":"Nicolson","year":"1978","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14740\/wjon1419","article-title":"Tumor dormancy: Biologic and therapeutic implications","volume":"13","author":"Balayan","year":"2022","journal-title":"World J. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tu, S.-M., Estecio, M.R., Lin, S.-H., and Zacharias, N.M. (2022). Stem cell theory of cancer: Rude awakening or bad dream from cancer dormancy?. Cancers, 14.","DOI":"10.3390\/cancers14030655"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00417-013-2377-5","article-title":"Upregulation of TGF-\u00df1 in experimental proliferative vitreretinopathy is accompanied by epithelial to mesenchymal transition","volume":"252","author":"Hoerster","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"200358","DOI":"10.1098\/rsob.200358","article-title":"Hallmarks of cancer\u2014The new testament","volume":"11","author":"Senga","year":"2021","journal-title":"Open Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"ref_77","first-page":"971","article-title":"Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus","volume":"34","author":"Wilden","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2022). Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030562"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sitta, J., Claudio, P.P., and Howard, C.M. (2022). Virus-based immuno-oncology models. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061441"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-012-0008-z","article-title":"Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: Preparing for the future","volume":"27","author":"Fournier","year":"2013","journal-title":"BioDrugs"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Guo, Z.S., Lotze, M.T., Zhu, Z., Storkus, W.J., and Song, X.-T. (2020). Bi- and tri-specific T cell engager-armed oncolytic viruses: Next-generation cancer immunotherapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8070204"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"14825","DOI":"10.33263\/BRIAC116.1482514852","article-title":"Oncolytic viruses as nanomedicines against the tumor microenvironment","volume":"11","author":"Zaheer","year":"2021","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11684-020-0750-4","article-title":"Development of oncolytic virotherapy: From genetic modification to combination therapy","volume":"14","author":"Lan","year":"2020","journal-title":"Front. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"849793","DOI":"10.3389\/fonc.2022.849793","article-title":"Retinoic acid induces an IFN-driven inflammatory tumor microenvironment, sensitizing to immune checkpoint therapy","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.vaccine.2010.12.005","article-title":"Antitumor vaccination by Newcastle disease virus hemagglutinin-neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity","volume":"29","author":"Ni","year":"2011","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/8.4.491","article-title":"Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B","volume":"8","author":"Umansky","year":"1996","journal-title":"Int. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.170.4.1814","article-title":"TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus","volume":"170","author":"Washburn","year":"2003","journal-title":"J. Immunol."},{"key":"ref_93","first-page":"3","article-title":"Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review)","volume":"36","author":"Schirrmacher","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.4049\/jimmunol.0903453","article-title":"Antiviral response dictated by a choreographed cascade of transcription factors","volume":"184","author":"Zaslavsky","year":"2010","journal-title":"J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.cgt.7700109","article-title":"Newcastle disease virus infection induces B7-1\/b7-2-independent T-cell costimulatory activity in human melanoma cells","volume":"7","author":"Termeer","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/eji.1830231032","article-title":"Viral hemagglutinin augments peptide-specific cytotoxic T cell response","volume":"23","author":"Ertel","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0008-8749(90)90302-8","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus: III. Potentiation of tumor-specific cytolytic T cell activation via induction of interferon a,\u00df","volume":"126","author":"Zawatzky","year":"1990","journal-title":"Cell. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Type I IFNs provide a third signal to CD8+ T cells to stimulate clonal expansion and differentiation","volume":"174","author":"Curtsinger","year":"2005","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1038\/s41467-021-25645-w","article-title":"Infection-induced type I interferons critically modulate the homeostasis and function of CD8+ na\u00efve T cells","volume":"12","author":"Jergovic","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3389\/fonc.2019.00436","article-title":"STAT3 contributes to oncolytic Newcastle disease virus-induced immunogenic cell death in melanoma cells","volume":"9","author":"Shao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2014.2692","article-title":"Strong T-cell costimulation can reactivate tumor-antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: Results from a phase I clinical study","volume":"46","author":"Schirrmacher","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/JVI.00211-09","article-title":"Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase","volume":"83","author":"Jarahian","year":"2009","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Liang, Y., Song, D.Z., Liang, S., Zhang, Z.F., Gao, L.X., and Fan, X.H. (2017). The hemagglutinin-neuraminidase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-kB. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178746"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/onc.2009.507","article-title":"Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus","volume":"29","author":"Puhlmann","year":"2010","journal-title":"Oncogene"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ceb.2015.04.016","article-title":"Secretory autophagy","volume":"35","author":"Ponpuak","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_106","first-page":"3612","article-title":"Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy","volume":"5","author":"Hu","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jcb.29871","article-title":"RAB5A is associated with genes involved in exosome secretion: Integration of bioinformatics analysis and experimental validation","volume":"122","author":"Moghimi","year":"2021","journal-title":"J. Cell. Biochem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.micpath.2018.12.047","article-title":"Detection of viral components in exosomes derived from NDV-infected DF-1 cells and their promoting ability in virus replication","volume":"128","author":"Xu","year":"2019","journal-title":"Microb. Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zhou, C., Tan, L., Sun, Y., Qiu, X., Meng, C., Liao, Y., Song, C., Liu, W., Nair, V., and Ding, C. (2019). Exosomes carry microRNAs into neighboring cells to promote diffusive infection of Newcastle disease virus. Viruses, 11.","DOI":"10.3390\/v11060527"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13337-020-00612-z","article-title":"Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death","volume":"31","author":"Hamzah","year":"2020","journal-title":"Virusdisease"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e004935","DOI":"10.1136\/jitc-2022-004935","article-title":"Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunoduppressive oncometabolic circuitry","volume":"10","author":"Nguyen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e004762","DOI":"10.1136\/jitc-2022-004762","article-title":"Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade","volume":"10","author":"Ju","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V., Van Gool, S., and Stuecker, W. (2019). Breaking therapy resistance: An update on oncolytic Newcastle disease virus for improvements of cancer therapy. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030066"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/jir.2012.0095","article-title":"The oncolytic activity of Newcastle disease virus infection in clear cell renal carcinoma cells in normoxic and hypoxic conditions: The interplay between von Hippel-Lindau and interferon-\u00df signaling","volume":"33","author":"Stanbridge","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resitant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/JVI.00401-09","article-title":"The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin","volume":"84","author":"Lazar","year":"2010","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.virol.2014.06.014","article-title":"ISG12a mediates cell response to Newcastle disease viral infection","volume":"462\u2013463","author":"Liu","year":"2014","journal-title":"Virology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12272-022-01389-z","article-title":"Crosstalk between angiogenesis and immune regulation in the tumor microenvironment","volume":"45","author":"Kim","year":"2022","journal-title":"Arch. Pharm. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2018.01.012","article-title":"Relevance of small GTPase Rac1 pathway in drug- and radio-resistance mechanisms: Opportunities in cancer therapeutics","volume":"124","author":"Cardama","year":"2018","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"28702","DOI":"10.18632\/oncotarget.25614","article-title":"Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus","volume":"9","author":"Oseledchyk","year":"2018","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-008-0526-1","article-title":"Efficiency of adjuvant active-specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial","volume":"58","author":"Schulze","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1586\/14760584.2014.854169","article-title":"Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: Long-term patient survival and mechanism of function","volume":"13","author":"Schirrmacher","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"734256","DOI":"10.3389\/fimmu.2022.734256","article-title":"Anti-tumor potency of short-term interleukin-15 dendritic cells is potentiated by in situ silencing of programmed-death ligands","volume":"13","author":"Versteven","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Zhang, L., Du, J., Song, Q., Zhang, C., and Wu, X. (2022). A novel in situ dendritic cell vaccine triggered by Rose Bengal enhances adaptive antitumor immunity. J. Immunol. Res., 1178874.","DOI":"10.1155\/2022\/1178874"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Chen, A., Wu, L., Luo, Y., Lu, S., Wang, Y., Zhou, Z., Zhou, D., Xie, Z., and Yue, J. (2022). Deep tumor penetrating gold nano-adjuvant for NIR-II-triggered in situ tumor vaccination. Small, e2200993.","DOI":"10.1002\/smll.202200993"},{"key":"ref_127","first-page":"1006","article-title":"A new strategy of cancer immunotherapy combining hyperthermia\/oncolytic virus pretreatment with specific autologous anti-tumor vaccination\u2014A review","volume":"2","author":"Schirrmacher","year":"2017","journal-title":"Austin Oncol. Case Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.gt.3303026","article-title":"Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy","volume":"14","author":"Janke","year":"2007","journal-title":"Gene Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1158\/1535-7163.MCT-20-0902","article-title":"Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity","volume":"20","author":"Harper","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.gt.3303095","article-title":"Generation of a recombinant Newcastle disease virus and expression of a full IgG antibody from two transgenes","volume":"15","author":"Willuda","year":"2008","journal-title":"Gene Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-015-0271-1","article-title":"Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice","volume":"34","author":"Wei","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_132","first-page":"951","article-title":"Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus","volume":"34","author":"Pfirschke","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12985-020-01326-w","article-title":"Oncolytic Newcastle disease virus delivered by mesenchymal stem cell-engineered system enhances the therapeutic effects altering tumor microenvironment","volume":"17","author":"Keshavarz","year":"2020","journal-title":"Virol. J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ijc.2910370416","article-title":"Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects","volume":"37","author":"Heicappell","year":"1986","journal-title":"Int. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00205796","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation","volume":"28","author":"Schild","year":"1989","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4049\/jimmunol.143.1.379","article-title":"Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity","volume":"143","author":"Kyewski","year":"1989","journal-title":"J. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"897750","DOI":"10.3389\/fmed.2022.897750","article-title":"Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment","volume":"9","author":"Delfanti","year":"2022","journal-title":"Front. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"104859","DOI":"10.1016\/j.isci.2022.104859","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Husman, T., Cen, X., Tsao, T., Brown, J., Bajpai, A., Li, M., Zhou, K., and Yang, L. (2022). Interleukin 15 in cell-based cancer immunotherapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137311"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e004713","DOI":"10.1136\/jitc-2022-004713","article-title":"Natural high-avidity T-cell receptor efficiently mediates regression of cancer\/testis antigen 83 positive common solid cancers","volume":"10","author":"Li","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/1078-0432.CCR-17-3061","article-title":"Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma","volume":"24","author":"Wildes","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12026-020-09167-z","article-title":"Tumor-infiltrating B cell is associated with the control of progression of gastric cancer","volume":"69","author":"Ni","year":"2021","journal-title":"Immunol. Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Cordell, E.C., Alghamri, M.S., Castro, M.G., and Gutmann, D.H. (2022). T lymphocytes as dynamic regulators of glioma pathobiology. Neuro Oncol., noac055.","DOI":"10.1093\/neuonc\/noac055"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1158\/1078-0432.CCR-17-2617","article-title":"Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes","volume":"24","author":"Mohme","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"850226","DOI":"10.3389\/fimmu.2022.850226","article-title":"Characterising distinct migratory profiles of infiltrating T-cell subsets in human glioblastoma","volume":"13","author":"Kollis","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic virus treatment in hig-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J. Neurooncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1200\/JCO.2004.09.038","article-title":"Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit","volume":"22","author":"Steiner","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_150","first-page":"1010","article-title":"The induction of immunogenic cell death (ICD) during maintenance chemotherapy and susequent multimodal immunotherapy for glioblastoma (GBM)","volume":"3","author":"Makalowski","year":"2018","journal-title":"Austin Oncol. Case Rep."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Van Gool, S.W., Makalowski, J., Bitar, M., Van de Vliet, P., Schirrmacher, V., and Stuecker, W. (2022). Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. Genes Immun.","DOI":"10.1038\/s41435-022-00162-y"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Van Gool, S.W., Makalowski, J., Fiore, S., Sprenger, T., Prix, L., Schirrmacher, V., and Stuecker, W. (2021). Randomized controlled immunotherapy clinical trials for GBM challenged. Cancers, 13.","DOI":"10.3390\/cancers13010032"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Van Gool, S.W., Makalowski, J., Bonner, E.R., Feyen, O., Domogalla, M.P., Prix, L., Schirrmacher, V., Nazarian, J., and Stuecker, W. (2020). Addition of multimodal immunotherapy to combination treatment strategies for children with DIPG: A single institution experience. Medicines, 7.","DOI":"10.3390\/medicines7050029"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Cao, J.X., Zhang, X.Y., Liu, J.L., Li, D., Li, J.L., Liu, Y.S., Wang, M., Xu, B.L., Wang, H.B., and Wang, Z.X. (2014). Clinical efficacy of tumor antigen pulsed DC treatment for high grade glioma patients: Evidence from a meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107173"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/13050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:04:16Z","timestamp":1760144656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/13050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":155,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232113050"],"URL":"https:\/\/doi.org\/10.3390\/ijms232113050","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}